Pharmacokinetics of IP vs IV Chemotherapy Using Small Molecule Protein Assembly Modulators
Abstract
Abnormal cells replicate uncontrollably and can form cancer, which is the second leading cause of death, after heart disease (American Cancer Society). It is important to find the most successful treatments for every type of cancer so that we can limit the number of lives affected or taken by the hungry cells. For the purpose of this poster, the treatments being talked about are 2 different types of small molecules, PAV-617 and PAV-951, both of which have antiviral activity against monkey pox and HIV. We analyzed a primary article (Lingappa, et al.) that looked into redefining these PAV variants as chemotherapy treatments. They found anticancer efficacy for both lung cancer and colorectal cancer, so we wanted to look into the pharmacokinetics (PK) of these 2 variants. We then took their published dataset and designed a 2 compartment PK model that compared IV vs IP routes of administration and hypothesized that the route of administration would affect the PK. We used a software called Monolix that is designed for nonlinear mixed-affects modeling as well as our own coding to create a PK model for IV and IP with these 2 variants. We found that clearance and volume are independent of route of administration. Looking at the pharmacokinetics of chemotherapies and applying them to pharmacometrics is crucial for the blurred line between pharmacology and medicine. It is important to analyze how the body responds to drugs and how different covariates affect this response so we can estimate dosing regimens for cancer patients.
Pharmacokinetics of IP vs IV Chemotherapy Using Small Molecule Protein Assembly Modulators
Abnormal cells replicate uncontrollably and can form cancer, which is the second leading cause of death, after heart disease (American Cancer Society). It is important to find the most successful treatments for every type of cancer so that we can limit the number of lives affected or taken by the hungry cells. For the purpose of this poster, the treatments being talked about are 2 different types of small molecules, PAV-617 and PAV-951, both of which have antiviral activity against monkey pox and HIV. We analyzed a primary article (Lingappa, et al.) that looked into redefining these PAV variants as chemotherapy treatments. They found anticancer efficacy for both lung cancer and colorectal cancer, so we wanted to look into the pharmacokinetics (PK) of these 2 variants. We then took their published dataset and designed a 2 compartment PK model that compared IV vs IP routes of administration and hypothesized that the route of administration would affect the PK. We used a software called Monolix that is designed for nonlinear mixed-affects modeling as well as our own coding to create a PK model for IV and IP with these 2 variants. We found that clearance and volume are independent of route of administration. Looking at the pharmacokinetics of chemotherapies and applying them to pharmacometrics is crucial for the blurred line between pharmacology and medicine. It is important to analyze how the body responds to drugs and how different covariates affect this response so we can estimate dosing regimens for cancer patients.
